Danegaptide

Drug Profile

Danegaptide

Alternative Names: GAP-134; GAP-Oral; ZP 1609

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Zealand Pharma
  • Developer Wyeth; Zealand Pharma
  • Class Antiarrhythmics; Cytoprotectives; Dipeptides; Small molecules
  • Mechanism of Action Gap junction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation; Myocardial reperfusion injury

Most Recent Events

  • 02 Mar 2016 Discontinued - Phase-II for Myocardial reperfusion injury (Prevention) in Denmark (IV)
  • 01 Dec 2015 Zealand Pharma completes a phase II trial in Myocardial reperfusion injury (Prevention) in Denmark (NCT01977755)
  • 28 Aug 2015 Zealand Pharma completes enrolment in its phase II trial for Myocardial reperfusion injury (Prevention) in Denmark (9183656; EudraCT2013-002312-27; NCT01977755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top